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Purpose: The sigma-1 receptor (σR1), a ligand-operated chaperone, has been inferred to be neuroprotective in previous
studies using σR1 ligands. The σR1 specificity of the protective function, however, has yet to be firmly established, due
to the existence of non-σR1 targets of the ligands. Here, we used the σR1-knockout mouse (Sigmar1−/−) to demonstrate
unambiguously the role of the σR1 in protecting the retinal ganglion cells against degeneration after acute damage to the
optic nerve.
Methods: Retinal σR binding sites were labeled with radioiodinated σR ligands and analyzed by autoradiography.
Localization of the σR1 was performed by indirect immunofluorescence on frozen retinal sections. Retinal ganglion cell
death was induced by acute optic nerve crush in wild-type and Sigmar1−/− mice. Surviving cells in the ganglion cell layer
were counted on Nissl-stained retinal whole mounts 7 days after the crush surgery.
Results: Photoaffinity labeling indicated the presence of the σR1 in the retina, in concentrations equivalent to those in
liver tissue. Immunolabeling detected this receptor in cells of both the ganglion cell layer and the photoreceptor cell layer
in wild-type retinas. Quantification of cells remaining after optic nerve crush showed that 86.8±7.9% cells remained in
the wild-type ganglion cell layer, but only 68.3±3.4% survived in the Sigmar1−/−, demonstrating a significant difference
between the wild-type and the Sigmar1−/− in crush-induced ganglion cell loss.
Conclusions: Our data indicated faster retinal ganglion cell death in Sigmar1−/− than in wild-type mice under the stresses
caused by optic nerve crush, providing direct evidence for a role of the σR1 in alleviating retinal degeneration. This
conclusion is consistent with the previous pharmacological studies using σR1 agonists. Thus, our study supports the idea
that the σR1 is a promising therapeutic target for neurodegenerative retinal diseases, such as glaucoma.
The  sigma-1  receptor  (σR1),  a  membrane  protein  of
26.2 kDa [1], represents a unique drug-binding site that has
no homology to any other known mammalian proteins [2]. It
is widely distributed in the central nervous system, including
the eye [3-6]. The sequence of the σR1 is highly conserved
across mammalian species, implicating fundamental biologic
function(s) [2]. The sigma-2 receptor (σR2) subtype has been
identified pharmacologically [7], but has yet to be cloned.
Although the σR1 signaling pathway(s) remain unclear,
it has been discovered that the σR1 is a Ca2+-sensitive and
ligand-operated  chaperone  primarily  residing  in  the
mitochondria-associated  endoplasmic  reticulum  (ER)
membrane [8]. Upon ER Ca2+ depletion caused by cellular
stresses,  the  σR1  dissociates  from  the  binding
immunoglobulin protein (BiP; another ER chaperone), and
becomes  available  to  regulate  inositol  trisphosphate  (IP3)
receptor-mediated  Ca2+  release  to  maintain  mitochondrial
Ca2+ homeostasis. The σR1 is therefore protective against
apoptosis.  Under  prolonged  cellular  stresses,  the  σR1
translocates to the extended ER network, whereby it interacts
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with and regulates the function of a variety of ion channels,
receptors, or kinases. Thus, the σR1 is proposed to function
as an interorganelle-signaling modulator [2].
Recently, a possible neuroprotective function of the σR1
has attracted growing interest. Some σR1 agonists have been
shown  to  attenuate  neuronal  loss  in  the  brain  upon  acute
neurodegeneration  [9,10],  and  also  to  promote  neurite
outgrowth of PC12 cells [11] and motoneurons [12]. The σR1
ligand-activated protective effects have also been explored in
the mouse and rat retinas, where the presence of the σR1
mRNA and its expression have been reported [4,5,13,14]. The
σR1 ligands dehydroepiandrosterone-sulfate (DHEA-S) and
PRE-084 attenuated retinal damage in rats [15,16]. Another
σR1  agonist,  (+)-pentazocine,  reduced  glutamate-initiated
cell death, in both cultured primary ganglion cells [17] and
RGC-5 cells [18,19]. When injected intraperitoneally into the
diabetic  mice,  (+)-pentazocine  reduced  retinal  lipid
peroxidation and cell loss in the ganglion cell layer [20]. These
reports shed light on the σR1 as a potential target for new
therapeutic agents to treat retinal neurodegeneration.
A variety of small molecules are known to bind the σR1,
and  some  of  them  have  been  used  for  pharmacological
interventions of disease states such as depression (for reviews,
see [21,22]). However, it is known that the σR1 ligands can
also bind to other receptors. For instance, even the highly
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1034σR1-selective  ligands  (+)-pentazocine  and  (+)-SKF-10047
have  alternative  targets  [22].  N,N-dimethyl  tryptamine
(DMT), which has been recently identified as an endogenous
ligand for the σR1 [23], is a more potent agonist for serotonin
receptors [24]. This complexity of drug-target interactions
often confounds the specificity and underlying mechanisms
of cellular or physiologic responses elicited by σR1 ligands.
It  is  thus  important  to  define  a  σR1-specific  protective
function. A direct approach to address this issue is to examine
retinal neurodegeneration in vivo in the Sigmar1−/− mouse
[25]. Although Sigmar1−/− mice do not show overt phenotypes
[25], under certain stress conditions, significant differences in
motor activities between the Sigmar1−/− and wild-type (WT)
have been observed [6,23].
In this study, we have generated stresses for ganglion
cells in Sigmar1−/− and WT mice by applying optic nerve
crush, which is an established model for acutely inducing an
apoptotic  program  similar  to  the  one  executed  in
glaucomatous retinal ganglion cells [26-28]. Comparison of
cell loss in the ganglion cell layer of Sigmar1−/− and WT mice
revealed a greater degree of ganglion cell death in the absence
of the σR1, demonstrating the σR1-specific protection against
cell death. Moreover, a high abundance of the σR1 in the
retina,  visualized  by  photoaffinity  labeling  and
immunostaining, also supports the σR1 as a potential target
for treating neurodegenerative retinal diseases.
METHODS
Source of animals: Oprs1 mutant (+/−) OprsGt(IRESBetageo)33Lex
litters on a C57BL/6J×129s/SvEv mixed background were
purchased from the Mutant Mouse Regional Resource Center,
UC  Davis,  CA,  from  which  homozygous  wild-type
(Sigmar1+/+)  and  σR1  knockout  (Sigmar1−/−)  mice  were
obtained through in-house breeding [6]. The genotypes were
confirmed by PCR. The primers for Sigmar1+/+: TCT GAG
TAC GTG CTG CTC TTC G and CAG AAA TCT CAG CCC
AGT ATC G. The primers for Sigmar1−/−: TCT GAG TAC
GTG CTG CTC TTC G and ATA AAC CCT CTT GCA GTT
GCA TC. All mice were maintained on a 4% fat diet (8604
M/R, Harland Teklad, Madison, WI) and subjected to standard
light cycles (12 h:12 h light-dark). The animals were handled
in accordance with animal care and use guidelines of the
University of Wisconsin, Madison, WI and in compliance
with  the  ARVO  Statement  for  the  Use  of  Animals  in
Ophthalmic and Vision Research.
Preparation of retinal homogenates: Mice were euthanized
by CO2 asphyxiation followed by cervical dislocation, and
eyes were enucleated immediately. Retinas were carefully
dissected  to  prevent  contamination  of  the  retinal  pigment
epithelium (RPE) cell layer. The retinas were minced and then
homogenized on ice with a glass homogenizer (Teflon pestle
by six slow passes at 3,000 rpm) in PBS buffer (10 mM
Na2HPO4/1.76 mM KH2PO4, pH 7.4, 137 mM NaCl, 2.68 mM
KCl) containing the Complete Protease Inhibitor Cocktail
(Roche, Indianapolis, IN). Homogenized tissues were then
centrifuged at 15,000× g for 10 s to remove cell debris. The
membrane  suspension  in  the  supernatant  was  snap-frozen
with dry ice/ethanol, and stored at −80 °C at a final protein
concentration of 20 mg/ml. Bovine retinal homogenates [29]
and rat liver membranes [30] were prepared as previously
described.  Protein  concentrations  of  the  retinal  and  liver
homogenates were determined by the Lowry protein assay.
Photoaffinity labeling: Radiochemical synthesis of the sigma
receptor  photolabel  [125I]-IAF  (1-N-(2’,6’-dimethyl-
morpholino)-3-(4-azido-3-[125I]iodo-phenyl  propane)  [30]
and [125I]-IACoc (3-iodo-4-azido cocaine) [31] was performed
as previously described. For photoaffinity labeling, retinal
homogenates were incubated in the presence and absence of
5 μM (+)- pentazocine in 60 mM Tris, pH 7.4, for 25 min at
22  °C,  then  [125I]-IAF  or  [125I]-IACoc  was  added  to  a
concentration of 1 nM and incubated for another 15 min.
Samples were irradiated for 6 s with a high-pressure AH6
mercury  lamp  (AH6-IC-30222;  Advanced  Radiation
Corpotation,  Santa  Clara,  CA),  and  the  reaction  was
immediately  quenched  with  the  sample  buffer  containing
250 mM β-mercaptoethanol. Proteins were separated on a
16.5% sodium dodecyl sulfate (SDS) gel (18 cm×16 cm), and
photolabeling  was  detected  by  PhosphorImager  (445  SI;
Molecular dynamics, Sunnyvale, CA).
Immunohistochemistry:  Following  euthanasia  of  the  mice,
their eyes were enucleated immediately and dissected. The
eyecups were fixed in 4% paraformaldehyde for 7 h, and then
cryoprotected in 30% sucrose in PBS for another 14 h, all at
4 °C. Cryosections of 10 μm each were cut from the eyecups
frozen  in  the  optimum  cutting  temperature  (O.C.T.)
embedding medium (Sakura Finetek 4583, Sakura Finetek
USA,  Inc.,  Torrance,  CA),  and  used  for  immunostaining
according to the method described previously [31] with minor
modifications. Briefly, retinal sections were permeabilized
with 1% Triton X-100 in PBS for 20 min, blocked with 10%
normal  goat  serum  (Cat#71–00–27;  Kirkegaard  &  Perry
Laboratories, Gaithersburg, MD) for 2 h at 22 °C, and then
incubated with purified rabbit anti-sigma-1 receptor antibody
(1/150  dilution)  [32]  and  mouse  monoclonal  anti-
synaptophysin (Cat. #MAB368, 1/500 dilution; Chemicon,
Los Angeles, CA) overnight at 4 °C. After rinsing the sections
3×,  secondary  antibodies  (Alexa-488  conjugated  goat-
antirabbit  and  Alexa-594-conjugated  goat-antimouse)  at
2 μg/ml was applied at 22 °C for 2 h. Sections were then rinsed
3×,  counterstained  with  4',6-diamidino-2-phenylindole
(DAPI) for 5 min, and mounted in the Prolong Gold mounting
medium (Invitrogen, Carlsbad, CA) and coverslipped. The
slides were left in the dark overnight and then sealed using
clear nail polish (Electron Microscopy Sciences, Hatfield,
PA). Microscopy of the retinal sections was first performed
on  a  Zeiss  Axiovert  200  M  epifluorescent  microscope
equipped with a 100× oil objective and the Axiovision 4.3
software (Carl Zeiss Light Microscopy, Göttingen, Germany).
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microscope (Nikon, Tokyo, Japan) supplied with a green 488
nm Argon laser and a red 561 nm DPSS laser through an
Apo60X  VC  oil-immersion  objective  with  NIS  elements
software [6]. Z-stacks were collected at 0.5 μm each, for a total
thickness  of  15  μm.  Sequentially  collected  images  were
stacked together in the ImageJ program using the standard
deviation option. Final figures were made in Adobe Illustrator
(Adobe Systems Inc., San Jose, CA).
Optic nerve crush and ganglion cell counting: The intraorbital
optic nerve crush surgery was conducted as described in detail
previously [27]. Experiments were performed using five age-
matched pairs (WT and Sigmar1−/−) of 6- and 12-month-old
mice. Prior to the crush surgery, mice were anesthetized by
intraperitoneal injection of 0.2 ml PBS solution containing
ketamine (6 mg/ml) and xylazine (0.4 mg/ml) [27]. In each
mouse, the left eye underwent surgery, while the right eye
served as an untreated control.
Cell loss was quantified from Nissl-stained images of
retinal  wholemounts  as  described  previously  [28]  and  is
expressed as a percentage of cells present in experimental
retinas relative to the untreated fellow retinas of the same
mice. Mice were euthanized, and the superior region of each
eye was marked with an ophthalmic cautery. The eye was
enucleated and fixed in 4% paraformaldehyde in PBS buffer
for 1 h at 22 °C. After rinsing the eyeball in PBS, the cornea
and lens were removed, the eyecup was incubated in PBS
containing 0.3% TritonX-100 (v/v) overnight at 22 °C. The
retina was then isolated, mounted with the ganglion cell layer
up on a glass “Plus” slide (Fisher Scientific, Chicago, IL), and
flattened under a coverslip with a 10 g weight on the top. Air-
dried retinas were stained with 1% cresyl violet acetate (Nissl
stain, in 0.25% acetic acid) by brush-painting, differentiated
and dehydrated in 100% ethanol, cleared in xylene, and finally
mounted  in  the  Prolong  Gold  mounting  medium  and
coverslipped.
We then counted cell numbers in the ganglion cell layer
using these retinal whole-mount slides. Digital images were
taken at 200× magnification using an Olympus BX40 light
microscope  (Olympus,  Mellville,  NY)  with  a  SONY
DXC-390 video camera attachment (Sony, New York, NY),
and imported into Image Pro Plus v4.5 (Media Cybernetics,
Inc., Silver Spring, MD) quantification software. Images were
taken in at least four microscopic fields (each encompassing
an area of 0.33 mm2) in the peripheral to midperipheral region
around the four quadrants of each retina. On each image, five
representative areas were chosen, and the cells in each area
were counted. The remaining cells in each treated eye were
then calculated as a percentage of the corresponding counts
of the untreated control.
Overall, approximately 10% of the cells present in each
retinal  whole-mount  were  counted,  providing  an  accurate
estimate of the loss of retinal ganglion cells after optic nerve
crush, as demonstrated by previous studies [27,28,33].
RESULTS
Sigma  receptor  binding  sites  in  the  retina  detected  by
photoaffinity labeling: While ligands have been frequently
used to target the σR1 in mouse and rat retinas in previous
studies [15,16,20,32,34], the ligand-binding properties of the
σR1 (and σR2) have not been thoroughly examined. Here, we
explored the retinal σR binding sites using radio-iodinated
photoreactive σR ligands [125I]-IACoc and [125I]-IAF. These
two photoaffinity probes have often been used to specifically
photolabel sigma receptors. [125I]-IACoc labels only the σR1,
whereas [125I]-IAF labels both the σR1 and the σR2 [23,30,
35,36]. The specificity of these probes for the σR1 has been
exhibited by the lack of specific photolabeling either in the
Sigmar1−/− samples or in the presence of (+)-pentazocine, a
potent σR1 ligand [23]. Specific labeling of the σR2 by [125I]-
IAF has been demonstrated by the protection of haloperidol,
which binds both the σR1 and the σR2 [23,30].
As  shown  in  Figure  1,  [125I]-IAF  specifically
photolabeled the σR1 (the 26 kDa band) in mouse retinal
homogenates (lane 1), because the labeling was blocked by
the presence of the σR1-specific ligand (+)-pentazocine (lane
2). Since bovine retinal homogenates can be readily prepared
to provide adequate samples for biochemical determinations,
we also used bovine samples to analyze the σR binding sites
in mammalian retinas. Similar to the results obtained from the
mouse retina, the σR1 was detected specifically by [125I]-IAF
(lanes 7 and 8) and [125I]-IACoc (lanes 3 and 4). The intensity
of  the  σR1  labeling  in  the  retina  (lanes  3  and  7)  was
comparable to that in the liver (lanes 5 and 9), which is known
to be rich in the σR1 and is often used for σR ligand-binding
studies [23,30,37].
Interestingly, unlike in the rat liver (lane 9), very low (if
any) σR2 was detected in either the bovine (lane 7) or mouse
(lane  1)  retina.  Since  the  σR2  has  not  been  cloned,
photoaffinity  labeling  represents  a  sensitive  approach  for
visualizing this subtype. However, considering that [125I]-IAF
labels the σR1 more efficiently than does the σR2 [30], this
data did not preclude the possibility of a σR2 presence that
might  have  been  undetectable.  More  experiments  are
underway to address this question.
High  abundance  of  the  sigma-1  receptor  in  the  retinal
ganglion cells demonstrated by immunostaining: Previous
immunohistochemical  studies  have  led  to  contradictory
results with regard to the presence of the σR1 in various types
of retinal neurons. For example, an earlier study showed the
σR1 presence in the photoreceptor nuclear region and the
inner segment [4], but in a more recent report, the σR1 was
not found in rat photoreceptor cells [5]. This discrepancy may
have arisen from technical issues such as sources of the σR1
antibodies, levels of background, et cetera. Here, we clarified
this using an antibody prepared against the full-length purified
σR1 protein that retained full [3H]-(+)-pentazocine binding
capacity [38]. Importantly, using the Sigmar1−/− mouse as a
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1036negative  control,  this  σR1  antibody  proved  to  be  highly
specific for immunostaining the σR1 in the mouse spinal cord
[6].
Figure 2 shows the side-by-side comparison of the σR1
immunostaining  in  WT  and  Sigmar1−/−  retinas;  both
experiments were performed under the same conditions. The
specificity of the σR1 staining in the WT retina (Figure 2A,C)
was manifested by the lack of green fluorescence from the
Sigmar1−/− control (Figure 2B,D). In agreement with previous
reports [4,5], the σR1 was highly expressed in the mouse
ganglion  cell  layer.  Remarkably,  the  outer  nuclear  layer,
which contains the photoreceptor nuclei, was also intensely
stained for the σR1. The staining was found mostly around the
nuclei.  This  result  was  consistent  with  an  early  report  of
mRNA presence and expression of the σR1 in the mouse outer
nuclear layer [4,13], but disagreed with a recent report that
concluded the absence of the σR1 in rat photoreceptor cells
[5].  Immunostaining  of  the  σR1  was  also  found  in  the
photoreceptor inner segment, albeit with a low intensity, but
not in the outer segment. Consistently, the σR1 has been
identified to be a molecular chaperone primarily residing in
the  ER  membrane  [8],  and  has  been  typically
immunolocalized in the ER network around the nucleus in
Chinese hamster ovary cells [8], retinal ganglion cells [4], and
Müller cells [39]. The photoreceptor outer segment, a highly
specialized compartment, does not contain an ER [31]. No or
very  low  level  of  σR1  was  detected  in  the  photoreceptor
synaptic terminals in the outer plexiform layer, which was
marked by the staining of synaptophysin (red, Figure 2A).
Thus,  our  data  demonstrated  the  σR1  expression  in
ganglion cells, as well as in photoreceptor cells. Our high
confidence  in  this  data  are  based  on  the  absence  of  σR1
staining in the Sigmar1−/− retina.
The ganglion cells in Sigmar1−/− mice are more susceptible to
optic nerve crush: To compare the susceptibility of WT and
Sigmar1−/− retinal ganglion cells to neurodegeneration, we
used the optic nerve crush surgery to induce acute ganglion
cell death [27]. The loss of ganglion cells after the surgery is
a continuous apoptotic process over an approximately three-
week period [28]. In consideration of possibly faster cell death
in Sigmar1−/− mice, we chose a time point of one week after
the crush surgery to examine cell loss in the ganglion cell
layer, in both WT and Sigmar1−/− retinas.
Degenerating  cells  appeared  7  days  after  the  crush
surgery, as characterized by the dense, fragmented nuclei
staining (Figure 3B,D). In contrast, in the untreated control
eyes, the nuclei in the ganglion cell layer showed an intact and
round healthy appearance (Figure 3A,C).
We then counted the remaining healthy cells on retinal
whole mounts. The densely stained fragmented nuclei (dying
cells) and spindle-shaped nuclei (vascular endothelial cells)
were excluded. The selection did not distinguish between
ganglion cells and large amacrine cells, but previous studies
have estimated the proportion of ganglion cells in this layer
to be 40%–60% of the neurons present [27,40,41].
There was no difference in cell density in the control eyes
of  the  12-month-old  WT  (34.02  cells/100  μm2)  and
Figure 1. Photoaffinity labeling of the
sigma-1 receptor in the retina. Shown
are autoradiograms of the photolabeled
retinal homogenates that were resolved
on  sodium  dodecyl  sulfate  gels.
Photoaffinity  labeling  of  σRs  in  the
mouse  retinal  homogenates  was
performed with [125I]-IAF (lanes 1 and
2).  In  bovine  retinal  homogenates,
[125I]-IACoc (lanes 3 and 4) and [125I]-
IAF  (lanes  7  and  8)  were  used,  and
labeling was compared to that in rat liver
membranes (lanes 5 and 6, 9 and 10,
respectively). The specificity of the σR1
photolabeling was demonstrated by the
reduced intensity in the presence of the
σR1 ligand (+)-pentazocine (the even-
numbered  lanes).  In  contrast,  the
nonspecifically  labeled  upper  bands
were not affected by (+)-pentazocine.
The typical labeling pattern of the σR1/
σR2 bands (seen in lane 9) have often
been observed previously in mouse and
rat  liver  membranes  [23,30].  In  each
lane of the gel, 200 μg of total protein
was loaded.
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1037Figure 2. The sigma-1 receptor distribution in the mouse retina. A: Immunostaining of the σR1 (green) in the WT mouse retina. B:
Immunostaining of the σR1 in the Sigmar1−/− mouse retina (negative control). C and D: The Nomarsky image superimposed with the staining
images in A and B, respectively. The abbreviations of the distinct cell layers are: OS, outer segment; IS, inner segment; ONL, outer nuclear
layer; OPL, outer plexiform layer; INL, inner nuclear layer, IPL, inner plexiform layer; GCL, ganglion cell layer. Synaptophysin was stained
(red) to mark the presynaptic terminals in the OPL and IPL. Immunostaining of the σR1 was performed on the mouse retinal cryosections
using the antibody raised against the full-length σR1 [6,32], followed by incubation with the Alexa-488 conjugated goat-antirabbit antibody.
WT and Sigmar1−/− mice of the same age (3 months) were used for preparation of retinal sections. Images were taken on a Nikon A1R laser
confocal microscope and processed using Adobe Photoshop.
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1038Sigmar1−/−  mice  (34.41  cells/100  μm2),  indicating  normal
development in both the WT and Sigmar1−/− ganglion cell
layers (also see Figure 3A,C).
In response to optic nerve crush, however, significantly
more  cells  were  lost  in  Sigmar1−/−  mice  one  week  after
surgery. Data pooled from 6- and 12-month-old animals used
in independent experiments (Figure 3E) indicated that WT
mice exhibited 86.8±7.9% (mean± standard deviation [SD])
cells remaining in experimental eyes (n=5), while Sigmar1−/
− mice exhibited 68.3±3.4% cells remaining (n=5) under the
same  conditions  (p=0.0013,  t-test).  Thus,  our  optic  nerve
crush  experiments  demonstrated  that  ganglion  cells  in
Sigmar1−/− mice underwent faster post-crush degeneration.
DISCUSSION
The  major  finding  in  this  in  vivo  study  is  the  increased
susceptibility of retinal ganglion cells to optic nerve crush-
induced cell death in the absence of the σR1. Because all the
neurons in the ganglion cell layer were counted, of which only
40%–60% are ganglion cells [27,40,41], the maximum level
of ganglion cell loss can reach only ~50% of the total counts
in the control. Considering this limit, an 18.5% difference of
Figure 3. Comparison of the post-crush
cell loss in the retinal ganglion cell layer
between WT and Sigmar1−/− mice. A-
D: Nissl-stained retinal whole-mounts
from WT (A and B) and Sigmar1−/− (C
and  D)  mice.  Images  were  from
representative  fields  (1,000×)  of  the
mid-peripheral  inferior  retinas  of  12-
month-old mice. For each mouse, while
the right eye served as untreated control
(A and C), the left eye was treated by
optic  nerve  crush  for  3  s  (B  and  D).
Retinal whole-mounts were prepared 7
days after surgery, and the side of the
ganglion cell layer was stained. Healthy
ganglion  cells  exhibited  larger  somas
and  nuclei  with  prominent  nucleoli.
Arrows  point  to  apoptotic  cells.  E:
Quantification of cells remaining in the
retinal ganglion cell layer one week after
surgery. The number of remaining cells
in the experimental eye is represented as
a percentage of the untreated control.
The data were pooled from three WT
and  Sigmar1−/−  pairs  of  6-month-old
mice  and  two  pairs  of  12-month-old
mice. There were 86.82±7.90% (mean
±standard  deviation  [SD],  n=5)  cells
remaining  in  WT  mice  and
68.31±3.36% remaining in Sigmar1−/−
mice. ** t-test, p=0.0013.
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1039cell loss between the WT and Sigmar1−/−is rather profound
(Figure 3E). Although protective factors other than the σR1
were possibly also involved, our results nevertheless support
a conclusion that the σR1 played a role in slowing down crush-
induced retinal ganglion cell degeneration.
This conclusion is also supported by previous studies
using  various  σR1  agonists.  In  a  recent  report,  through
intraperitoneal injection of a σR1 agonist, (+)-pentazocine,
into diabetic mice, Smith et al. observed attenuated cell loss
in the ganglion cell layer of retinal sections [20]. Less retinal
damage has been observed also in rats following injection of
other σR1 agonists, that is, PRE-084, neurosteroids, and an N-
methyladamantan-1-amine derivative [(-)-MR22] [15,16,32].
Additionally, consistent evidence has been produced using
primary ganglion cells [17] or RGC-5 cells [18,19], in which
(+)-pentazocine mitigated cell death that was caused by the
excitotoxins glutamate and homocysteine. Importantly, the
current study confirms that the σR1 is a bona fide in vivo target
that attenuates stress-induced retinal ganglion cell death.
It is interesting to note that under normal conditions there
was no developmental difference between Sigmar1−/− and WT
mice in their retinas, as indicated by essentially the same cell
density in the ganglion cell layer in the Sigmar1−/− (34.41
cells/100 μm2) and the WT (34.02 cells/100 μm2). But under
stress conditions exerted by optic nerve crush, a significant
protective effect of the σR1 could be observed (Figure 3E).
The σR1 is ubiquitously expressed in various mammalian
tissues,  and  its  sequence  is  highly  conserved  across
mammalian species [1,2], as well as in zebrafish. The σR1 is
thus believed to play prominent cellular and physiologic roles
[2]. But it has been puzzling that there was no overt phenotype
found  when  the  Sigmar1−/−mouse  model  first  became
available  [25].  It  is  thereby  speculated  that  compensatory
mechanisms  involving  the  σR2  or  other  pathways  are
activated in the Sigmar1−/− mouse. Remarkably, however,
some phenotypes of the Sigmar1−/− mouse could be observed
when  the  animals  were  challenged  by  injection  of  σR1-
binding  drugs  [23,25]  or  by  forced  swimming  [6].
Furthermore,  here  we  showed  a  phenotype  of  greater
susceptibility of ganglion cells to degeneration in Sigmar1−/
− mice when stressed by acute optic nerve crush (Figure 3E).
Thus, it appears that the physiologic functions of the σR1,
such as protection against ganglion cell death, are stimulated
and become discernable under stressful conditions.
This stress-stimulated σR1 cellular protective action is
consistent  with  its  recently  discovered  role  as  a  ligand-
operated chaperone [8]. The σR1 resides in the mitochondria-
associated ER membrane, and maintains mitochondrial Ca2+
homeostasis by chaperoning the IP3 receptor type 3 in the
membrane,  thus  regulating  its  lifetime.  Under  various
stressful conditions, the σR1 was found to translocate to the
extended  ER  network  [2,42],  including  the  ER  structure
opposing the plasma membrane, whereby the σR1 is believed
to be able to chaperone other proteins or regulate the functions
of various ion-channels, receptors, and kinases. This probably
occurs through direct interactions under some circumstances
[6,8,43-48].
The  molecular  function  of  the  σR1  as  a  chaperone/
signaling modulator implies underlying mechanisms of the
σR1-specific protection against the cell death observed here
(Figure 3). First, the chaperoning activity of the σR1 may help
contain  unfolded  protein  responses  that  often  lead  to
overproduction of the reactive oxygen species (ROS). While
ROS is elevated during retinal ganglion cell degeneration
[49], σR1 agonists have been found to suppress oxidative
damage in the retina [20,50]. Second, since the crush-induced
ganglion  cell  death  has  been  previously  characterized  as
apoptotic  [33,51],  the  σR1  may  alter  gene  expression  in
apoptosis pathways indirectly, by regulating ROS or Ca2+
levels. Evidence can be found from a recent report suggesting
that  the  σR1  promoted  cell  survival,  at  least  in  part  by
transcriptionally regulating Bcl-2 expression via the ROS/NF-
kappaB pathway in Chinese hamster ovary cells [52]. Bcl-2
and Bax are two important gene families in the determination
of the life and death of the cell [33]. Bcl-2 at high levels is
often  anti-apoptotic,  whereas  expression  of  Bax,  up  to  a
certain  threshold,  triggers  cell  death  [53].  In  another
independent study, activation of the σR1 inhibited the increase
of Bax expression in RGC-5 cells after glutamate treatments,
likely  by  maintaining  Ca2+  homeostasis  [19].  While
explanations in these studies using cultured cells are plausible,
the mechanism(s) underlying the protective action of the σR1
may differ in vivo in the retinal ganglion cells, where Bcl-x
rather  than  Bcl-2  is  predominantly  expressed  [54].
Alternatively, the σR1 may suppress the N-Methyl-D-aspartic
acid  (NMDA)  currents  of  the  ganglion  cells  to  counter
excitotoxicity [34]. Further investigations are warranted to
identify  the  major  molecular  mechanism(s)  of  the  σR1-
mediated protection for the ganglion cells, preferably using
Sigmar1−/− mice.
Another interesting finding in this study is the presence
of the σR1 in the photoreceptor cells (Figure 2), solving a
controversy  that  arose  from  previous  reports  [4,5].  This
information raises the real possibility of using σR1-targeting
therapeutic  interventions  to  attenuate  photoreceptor
degeneration, which is the cause of a major blinding disease
—retinitis  pigmentosa  [55].  Meanwhile,  the  same
immunostaining experiments indicated a high abundance of
σR1  in  the  ganglion  cells  (Figure  2).  While  confirming
previous  reports  [4,5],  this  data  also  provided  additional
evidence supporting the cellular protective action of the σR1
(Figure 3). More importantly, abundant σR1 in mammalian
retinas,  as  detected  by  both  photolabeling  (Figure  1)  and
immunohistochemistry  (Figure  2),  offer  a  valid  target  for
pharmacological  interventions.  In  support  of  in  vivo  σR1
regulations, several candidates of endogenous σR1 ligands
have been identified, such as DMT [23], neurosteroids [22],
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1040and sphingosine [56]. Thus, activation of the σR1 using highly
selective drugs may provide a practical approach to alleviating
retinal neurodegeneration.
In  conclusion,  from  our  in  vivo  experiments  using
Sigmar1−/− and WT mice, and optic nerve crush surgery to
induce cell death, we defined a specific role for the σR1 in
containing  retinal  ganglion  cell  degeneration.  Since  optic
nerve  crush  specifically  triggers  ganglion  cell  death  that
resembles apoptosis in glaucoma [27,28]—a major cause of
blindness—the current study suggests that the σR1 may be a
potential target for developing new therapies for treating this
eye disease.
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